SCHEMBL1368682

SCHEMBL1368682

CC(C)(C)OC(=O)c1ccc(Cl)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.50
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
NOTUM Q6P988 1/20 0.43
RHEB Q15382 2/20 0.42
SLC7A5 Q01650 1/20 0.40
ALDH1A1 P00352 3/20 0.40
ALOX15 P16050 1/20 0.39
CNR2 P34972 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15557828 0.87 STAT3 (0.47) STAT3CA12CA1CA2CA9
SCHEMBL3527319 0.81 LMNA (0.51) CA12CA1CA2CA9CA14
SCHEMBL10776576 0.81 ESR1 (0.55) STAT3CA12CA1CA2CA9
SCHEMBL7594883 0.81 CA12 (0.46) STAT3CA12CA1CA2CA9
SCHEMBL24220446 0.81 STAT3 (0.51) STAT3CA12CA1CA2CA9
SCHEMBL14426491 0.81 STAT3 (0.48) STAT3CA12CA1CA2CA9
SCHEMBL27594947 0.81 STAT3 (0.48) STAT3CA12CA1CA2CA9
SCHEMBL32477600 0.81 ALDH1A1 (0.58) CA12CA1CA2CA9CA14
SCHEMBL728817 0.81 ALDH1A1 (0.58) CA12CA1CA2CA9CA14
SCHEMBL2686416 0.80 ALOX15 (0.50) STAT3CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
CN-110740991-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2023-07-04 CN disclosed
EP-3632443-B1 ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-07 EP disclosed
EP-3381896-B1 BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2023-01-18 EP disclosed
US-11510915-B2 Anti-tumor effect potentiator using novel biphenyl compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-11-29 US disclosed
US-11479563-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-10-25 US disclosed
CN-108602770-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2022-02-08 CN disclosed
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-10723742-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-07-28 US disclosed
EP-3632897-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
EP-3633380-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
CN-110740991-A Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2020-01-31 CN disclosed
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-12-13 US disclosed
EP-3381896-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2018-10-03 EP disclosed
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US disclosed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed
CN-101511828-A Heteroaryl derivatives as protein kinase inhibitors HOFFMANN LA ROCHE (CH) 2009-08-19 CN disclosed
EP-2064213-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2009-06-03 EP disclosed
WO-2008028617-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND KDM1B, KDM1A, DOT1L STAT3 176/4885CA12 3593/4885CA1 2561/4885
US-10723742-B2 Biphenyl compound or salt thereof KDM1B, BMI1, HDAC1 STAT3 102/4885CA12 2814/4885CA1 2194/4885
US-11479563-B2 Biphenyl compound or salt thereof BMI1, KDM1B, KDM1A STAT3 98/4885CA12 2911/4885CA1 2427/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B STAT3 4451/4885CA12 4680/4885CA1 4253/4885
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, HDAC1, DOT1L STAT3 123/4885CA12 3302/4885CA1 2386/4885
US-11510915-B2 Anti-tumor effect potentiator using novel biphenyl compound KDM1B, KDM1A, DOT1L STAT3 176/4885CA12 3593/4885CA1 2561/4885
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, KDM1A, HDAC1 STAT3 101/4885CA12 3152/4885CA1 2661/4885
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, PRKACA STAT3 1453/4885CA12 4880/4885CA1 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.